MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
CONMED Corporation Operating Income 2011-2026 | CNMD
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income CONMED Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 200 M | 121 M | 70.1 M | 110 M | 46 M | 79.1 M | 71.3 M | 46.9 M | 37.7 M | 51.2 M | 52.8 M | 56.5 M | 65.2 M | 8.27 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 8.27 M | 72.5 M |
Quarterly Operating Income CONMED Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.9 M | 38.2 M | 16 M | 65.7 M | 47.1 M | 35 M | 30.3 M | 27.4 M | 12.7 M | - | 24.2 M | 24.5 M | 22.4 M | - | 26.7 M | 25.7 M | 20.1 M | - | 29.4 M | -21.2 M | 13.2 M | - | 20.9 M | 18.7 M | 11.6 M | - | 11.5 M | 16.7 M | 17.3 M | - | 13.5 M | 12.8 M | -2.49 M | - | 13.8 M | 7.68 M | 3.54 M | - | 14.8 M | 12.4 M | 11 M | - | 2.45 M | 15.9 M | 17.3 M | - | 8.8 M | 15.7 M | 15.9 M | - | 14.1 M | 17.1 M | 17 M | - | 15.9 M | 16.7 M | 17.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 65.7 M | -21.2 M | 17.9 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AxoGen
AXGN
|
-3.29 M | $ 32.61 | - | $ 1.44 B |  USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 6.87 | - | $ 493 M |  Israel |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.82 | -2.55 % | $ 132 M | USA |
 |
Alphatec Holdings
ATEC
|
-136 M | $ 13.1 | - | $ 1.87 B | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.77 | - | $ 178 M |  France |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Bio-Rad Laboratories
BIO
|
269 M | $ 292.42 | - | $ 8.25 B | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Bruker Corporation
BRKR
|
253 M | $ 37.51 | - | $ 5.59 K | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
2.6 B | $ 74.12 | - | $ 109 B | USA |
 |
Abbott Laboratories
ABT
|
6.82 B | $ 111.47 | - | $ 194 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 13.04 | - | $ 352 M | USA |
 |
InMode Ltd.
INMD
|
113 M | $ 14.3 | - | $ 1.13 B | Israel |
 |
IRadimed Corporation
IRMD
|
22 M | $ 99.84 | - | $ 1.26 B | USA |
 |
Integer Holdings Corporation
ITGR
|
208 M | $ 85.36 | - | $ 2.87 B | USA |
 |
Electromed
ELMD
|
9.66 M | $ 23.31 | - | $ 197 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
Pulmonx Corporation
LUNG
|
-57.7 M | $ 1.42 | -2.07 % | $ 55.5 M | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Penumbra
PEN
|
9.28 M | $ 338.72 | - | $ 13.1 B | USA |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Insulet Corporation
PODD
|
309 M | $ 240.82 | - | $ 16.9 B | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.54 | -0.22 % | $ 122 M | USA |
 |
Sintx Technologies
SINT
|
-13.4 M | $ 2.72 | - | $ 10.2 M | USA |
 |
Globus Medical
GMED
|
166 M | $ 87.22 | - | $ 11.8 B | USA |
 |
Smith & Nephew plc
SNN
|
593 M | $ 35.53 | - | $ 23.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
8.09 M | $ 4.65 | - | $ 75.9 M | USA |
 |
Stryker Corporation
SYK
|
4.89 B | $ 365.85 | - | $ 140 B | USA |